Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 1.40M
ATRA Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Atara Biotherapeutics, Inc.NASDAQ: ATRA
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash declines year over year
Q1 FY2026 net change in cash of $122K (cash outflow) fell 98.9% year over year, behind the -73.5% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Net change in cash amounted to 13.8% of revenue in FY2025, up 13.2 pp from a year earlier.
- Net change in cash grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -98.9% toward the trailing-twelve-month pace of -73.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (16.69M) USD
- Year-over-year change
- -1958.4%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.69M) | -1958.4% |
| FY2024 | 2024-12-31 | (811K) | +98.8% |
| FY2023 | 2023-12-31 | (67.1M) | -366.3% |
| FY2022 | 2022-12-31 | (14.39M) | +84.7% |
| FY2021 | 2021-12-31 | (94.32M) | — |
Net Change in Cash vs competitors
How ATRA compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -73.5% is the 6th highest of 11, against a peer median of -105.6%.
- Net change in cash amounts to 24.3% of revenue for ATRA, versus a peer median of 607.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $79.05M USD | -221.2% | +105.0% | 50.3% | |
| LTM Mar 2026 | $72.93M USD | +856.8% | -54.9% | 1024.0% | |
| LTM Mar 2026 | $61.31M USD | -209.6% | -38.7% | — | |
| LTM Mar 2026 | $34.82M USD | -143.9% | +26.2% | — | |
| LTM Mar 2026 | $32.55M USD | -179.4% | — | 32.7% | |
| LTM Mar 2026 | $29.52M USD | +295.4% | -58.6% | 2952.1% | |
| LTM Mar 2026 | €22.84M EUR | -203.0% | -73.8% | 77884.9% | |
| LTM Mar 2026 | $15.19M USD | +3411.8% | +74.6% | 191.4% | |
| LTM Mar 2026 | $5.63M USD | -73.5% | +5.1% | 24.3% | |
| LTM Jan 2026 | $3.93M USD | +410.0% | +18.4% | 6.8% | |
| LTM Mar 2026 | $3.89M USD | -67.3% | -39.8% | 2905.2% | |
| Peer median (excluding ATRA) | — | -105.6% | -38.7% | 607.7% | |
Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (340.14M) | (228.3M) | (276.13M) | (85.4M) | 32.69M |
| Depreciation & Amortization | 9.35M | 5.65M | 4.83M | 5.05M | 2.38M |
| Deferred Income Tax | 1.79M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 53.87M | 53.84M | 45.39M | 27M | 9.75M |
| Change in Working Capital | 52.58M | (61.47M) | 15.34M | (30.96M) | (104.74M) |
| Accounts Receivables | 264K | (39.24M) | 6.11M | 32.63M | 229K |
| Inventory | 3.34M | (1.59M) | (8.12M) | (4.43M) | 10.66M |
| Accounts Payables | 9.07M | (9.21M) | (3.13M) | 687K | (4.24M) |
| Other Working Capital | 39.91M | (11.44M) | 20.48M | (59.84M) | (111.38M) |
| Other Non-Cash Items | 2.04M | (40.15M) | 17.59M | 15.59M | 8.98M |
| Operating Cash Flow | (220.52M) | (270.43M) | (192.98M) | (68.72M) | (50.94M) |
| Capital Expenditures | (10.58M) | (4.19M) | (1.22M) | (246K) | 0 |
| Acquisitions (Net) | (32.84M) | 0 | 0 | 0 | 948K |
| Purchases of Investments | (301.13M) | (180.59M) | (83.65M) | (19.67M) | (7.89M) |
| Sales of Investments | 333.97M | 292.97M | 208.71M | 28.54M | 25.09M |
| Other Investing Activities | 32.84M | 94.77M | 25K | 0 | 0 |
| Investing Cash Flow | 22.26M | 202.96M | 123.87M | 8.62M | 18.15M |
| Debt Repayment | (254K) | (518K) | (947K) | (892K) | (250K) |
| Common Stock Issued | 98.7M | 21.89M | 2.14M | 59.95M | 16.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.5M | 31.71M | 821K | 223K | (1K) |
| Financing Cash Flow | 103.94M | 53.08M | 2.01M | 59.28M | 16.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (94.32M) | (14.39M) | (67.1M) | (811K) | (16.69M) |
| Free Cash Flow | (231.1M) | (274.62M) | (194.2M) | (68.96M) | (50.94M) |
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.